Philadelphia, Pennsylvania – Plexus Ventures announces the successful completion of two important partnering projects:
ONE MORE SUCCESSFUL DIVESTMENT OF MATURE PRODUCTS
Plexus provided professional services to Reckitt Benckiser (www.rb.com) in their divestment of a number of brands including Earex and Derbac M to Lanes Health, a family-owned consumer health business headquartered in the UK.
Additional details regarding the transaction, taken from Lanes Health January 5, 2014 press release are included below:
LANES HEALTH ADDS BRANDS TO ITS PORTFOLIO
Family-owned consumer health business, Lanes Health, has today announced its acquisition of a number of brands including Earex and Derbac M from RB plc, for an undisclosed sum. Earex is used in the relief of pain caused by inflammation, and Derbac M used to treat head lice and other infestations. Both brands complement the Lanes Health existing portfolio which includes Olbas, Kalms and Jakemans. Commenting on the deal, Dave Cole, Sales & Marketing Director of Lanes Health said, “This is a significant acquisition for us which will support our ambition to be one of the leading family owned consumer health businesses in the UK. We are delighted to bring these brands into the Lanes Health range.” Earex and Derbac M will be managed and distributed by Lanes Health from 9th January 2015.
BROAD OUT-LICENSING AGREEMENT
Plexus supported a European family-owned pharmaceutical company to out-license their innovative ophthalmology product to a well-established player in that therapeutic area. The deal covers Europe and several other extra-European territories. The companies, both privately –owned, have decided not to announce the agreement. Plexus assisted the licensor throughout the process of identifying potential licensees, qualifying them, supporting the client’s selection process and negotiating a definitive agreement.
